“3 years of tralokinumab treatment provides long term disease control as demonstrated by clinically meaningful outcomes in modera te to severe atopic dermatitis”, J of Skin, vol. 7, no. 2, p. s142, Mar. 2023, doi: 10.25251/skin.7.supp.142.